Central Pharmaceutical Joint Stock Company No3 (DP3) Q4 2025 earnings summary

Executive summary

• Net revenue for 2025 reached VND 438.0 billion, up from VND 417.5 billion year-over-year, with Q4 net revenue at VND 131.6 billion, a 13% increase from Q4 2024.

• Net profit after tax for 2025 was VND 153.6 billion, up 26.8% from VND 121.2 billion in 2024.

• Total assets at year-end 2025 were VND 607.8 billion, down from VND 756.2 billion at the start of the year.

Financial highlights

• Gross profit for 2025 was VND 287.7 billion, up from VND 276.1 billion in 2024.

• Operating profit for 2025 reached VND 192.6 billion, a 26.8% increase year-over-year.

• EPS for 2025 was VND 7,142, compared to VND 5,636 in 2024.

• Cash and cash equivalents at year-end were VND 4.5 billion, down from VND 13.7 billion at the start of the year.

Outlook and guidance

• The company continues to focus on pharmaceutical production, trading, and expansion of commercial services.